How Do Pharma Companies Build an Accurate HCP Targeting Model?

An accurate HCP targeting model does more than rank physicians by prescription volume. It combines prescribing behavior, patient potential, specialty, payer access, engagement history, competitive activity, and territory context to identify healthcare professionals with meaningful current or future commercial potential.
For pharma companies, the challenge is not simply finding high-prescribing physicians. It is determining which HCPs should be prioritized, why they matter, and how commercial teams should engage them.
Perceptive Analytics' commercial analytics framework approaches HCP targeting as a progression from static deciles to multi-factor segmentation, predictive propensity scoring, and next best action.
What is HCP targeting in pharma?
HCP targeting is the process of identifying and prioritizing healthcare professionals based on factors such as prescribing behavior, patient population, commercial potential, and likelihood to respond to engagement.
A useful model should answer four practical questions:
Who is prescribing the product or its competitors?
Who treats patients who could benefit from the product?
Which HCPs have the potential to increase prescribing?
Which HCPs should receive field, digital, or other commercial engagement?
Prescription volume is a useful starting point, but it does not tell the entire story. An HCP with modest historical prescribing may have a large relevant patient population or show increasing category activity. That future potential can be missed when targeting relies only on historical volume.
What data goes into an accurate HCP targeting model?
An effective model usually combines multiple data sources rather than relying on a single prescribing dataset.
Data category
What it tells the model
Example signal
Prescription data
Historical prescribing behavior
TRx, NRx, market share
Medical claims
Patient and treatment activity
Relevant patient volume
HCP profile data
Physician identity and context
Specialty, practice, affiliation
Patient data
Potential treatment population
Disease and treatment patterns
CRM data
Existing engagement
Calls, responses, samples
Payer data
Access conditions
Formulary status, restrictions
Digital engagement
Channel behavior
Email or digital response
Territory data
Local commercial context
HCP density, opportunity
Competitive data
Brand and category behavior
Competitor prescribing
Network data
Relationships and influence
Referral or affiliation patterns

The value comes from connecting these signals. Historical prescriptions show what an HCP has done, while patient, payer, engagement, and competitive data can provide additional context around what the HCP may do next.
This also makes identity resolution critical. Data from CRM, claims, prescription feeds, payer sources, and other systems needs to connect to the same HCP record. Without that connection, activity can be fragmented across multiple records and distort the resulting score.
Why isn't prescription data alone enough?
Prescription volume is backward-looking.
Consider two physicians. Physician A writes a high number of prescriptions today but treats relatively few patients relevant to a new indication. Physician B has lower historical volume but treats a larger relevant patient population and has recently shown increased activity in the category.
A volume-based model may rank Physician A higher. A broader targeting model could identify Physician B as an emerging growth opportunity.
This is why patient potential, specialty, treatment behavior, payer access, engagement, and competitive context should be considered alongside prescription volume. The attached source also describes multidimensional HCP profiles that incorporate factors such as patient mix, prescribing behavior, promotion response, attitudes, and payer reimbursement.
How do pharma companies build an HCP targeting model?
A practical process can be organized into seven stages:
Define the commercial objective → Build the HCP universe → Integrate data → Segment HCPs → Score potential → Validate targets → Activate and refresh

1. Start with the commercial objective The first step is to define what the model needs to accomplish. Depending on the brand and market, the objective could be: Increase NRx for a new brand Increase share among high-value specialists Identify underpenetrated HCPs Improve field-force productivity Find HCPs with high patient potential Expand into a new indication Identify potential adopters Improve omnichannel engagement Reallocate calls toward higher-potential HCPs The objective determines which variables matter and how the model should be structured. A targeting model designed for a product launch may use different inputs and thresholds from one built for an established brand.
2. Define the HCP universe Before scoring physicians, pharma teams need to establish who is eligible for consideration. Common filters include: Specialty Geography Practice setting Relevant diagnosis or treatment activity Patient population Product eligibility Affiliation Existing targeting rules Compliance or suppression requirements This step is easy to underestimate. A sophisticated model cannot compensate for an incomplete or inaccurate HCP universe.
3. Integrate and resolve HCP data Commercial data is often distributed across multiple environments. The model needs an identity-resolved HCP record that brings these sources together. A typical data flow looks like: HCP master → Prescribing → Claims → Patient potential → CRM engagement → Payer access → Competitive activity → Targeting score The goal is to give commercial teams one consistent view of each physician rather than several disconnected records. This is also where data visualization and reporting become useful. A well-governed analytics environment can help commercial teams monitor target movement, review model outputs, and connect targeting decisions with business outcomes. Depending on the organization's technology environment, this may involve Power BI consulting alongside the underlying commercial analytics work.
4. Segment HCPs Segmentation groups HCPs according to meaningful differences in behavior, potential, needs, or commercial value. Targeting then determines which HCPs or segments should receive commercial investment. For example: Tier HCP characteristics Potential engagement Tier 1 High current value and high future potential Highest field priority Tier 2 Moderate current value with strong growth potential Field and digital engagement Tier 3 Lower current value but relevant patient opportunity Selective digital engagement Tier 4 Limited current or future opportunity Lower-touch engagement

The exact tiers should be tied to the brand's commercial objective. An HCP who is highly relevant for one indication may not have the same priority for another.
Should pharma companies use deciles or predictive targeting?
It does not have to be an either-or decision.
Deciles can provide a useful baseline, while broader models add patient, engagement, payer, competitive, and other signals.
A typical progression is:
Static deciles → Multi-factor segmentation → Predictive propensity scoring → Dynamic targeting
Static deciles
Deciles rank HCPs according to historical prescription volume.
Advantages:
Easy to explain
Easy to operationalize
Familiar to field teams
Limitations:
Backward-looking
May miss emerging prescribers
Does not capture every patient or engagement signal
Multi-factor segmentation
This approach adds variables such as patient potential, specialty, payer access, and engagement.
It provides more context and can support differentiated engagement, but it requires greater data integration and can become unnecessarily complicated if too many weak variables are included.
Predictive targeting
Predictive models use historical patterns to estimate future HCP potential.
They can help identify emerging opportunities that prescription volume alone may miss. At the same time, they require sufficient data, validation, and an approach that commercial teams can understand.
The attached source describes dynamic HCP segmentation using machine learning or AI-powered models to segment HCPs according to their potential to drive impact.
How can AI improve HCP targeting?
AI and machine learning can evaluate combinations of signals that are difficult to assess manually.
Depending on the use case, a model may consider:
Historical prescribing
Prescribing trajectory
Patient population
Specialty
Competitive behavior
Payer environment
Prior engagement
Channel response
Geographic characteristics
HCP affiliations
The output could estimate the probability of increased prescribing or expected commercial potential.
That is different from simply ranking physicians according to last year's prescription volume.
From targeting to next best action
Identifying a high-potential HCP is only one part of the process.
The next question is: what should the commercial team do with that HCP?
A next best action framework can help determine:
Whether the HCP should be contacted
Which channel should be used
What type of content may be appropriate
How frequently to engage
When to engage
Whether field or digital interaction is more suitable
This creates a progression from “Who should we target?” to “What should we do with each target?”
A targeting model can therefore be statistically strong and still have limited commercial value if its output never reaches the field or marketing workflow.
How should pharma companies validate an HCP targeting model?
Model performance should be tested against actual commercial outcomes, not just statistical measures.
A useful validation process includes five areas:

1. Historical validation Test whether the model would have identified high-potential HCPs using historical data.
2. Holdout validation Evaluate the model using data that was not used during development to see whether it generalizes.
3. Business validation Compare model rankings with outcomes such as prescribing growth or engagement response.
4. Field validation Ask experienced field teams whether the resulting targets make practical sense. Their feedback can reveal issues that statistical testing may not capture.
5. Outcome validation Measure whether the new targeting approach produces better outcomes than the previous method. Useful KPIs include: Incremental prescriptions NRx growth TRx growth Market share Call productivity HCP engagement Response rate Target-list penetration Cost per productive interaction The objective is not simply to produce a high predictive score. The model needs to improve commercial decisions. How often should HCP targeting be refreshed? HCP targeting should reflect how quickly physician behavior and the surrounding market change. Relevant changes can include: Prescription behavior HCP affiliations Patient activity Payer coverage Competitive launches Engagement response The source cites an IQVIA finding that up to 40% of HCPs can change segments within six months. That illustrates why a target list created once and left untouched can lose relevance. This does not mean the entire model needs to be rebuilt every month. A better approach is to separate model monitoring and recalibration from target-list activation. For example: Monitor continuously → Investigate changes → Recalculate scores → Validate material changes → Update target lists → Measure outcomes What are the common mistakes in HCP targeting? Even sophisticated programs can lose value through basic execution problems.
6. Using only prescription volume This creates a historical view of HCP value and can miss emerging opportunities.
7. Treating every HCP the same A specialist treating a large relevant patient population may require a different engagement approach from a high-volume generalist.
8. Ignoring payer access Formulary status, prior authorization, and other access conditions can affect prescribing potential.
9. Building the model once Physician behavior, affiliations, patient populations, competition, and access conditions change over time.
10. Creating outputs that field teams cannot use A complex score without an actionable recommendation can become another analytics report rather than a useful commercial capability.
11. Measuring model performance instead of business impact A strong statistical model does not automatically produce incremental prescriptions.
12. Poor HCP identity resolution If one physician appears as multiple records across CRM, claims, and other systems, their activity may be fragmented and misinterpreted. How should HCP targeting connect with omnichannel engagement? HCP targeting should not end with a target list. A practical framework connects: HCP potential → Segment → Channel preference → Message → Frequency → Engagement → Prescription outcome → Model feedback For example, a high-potential HCP who responds well to field activity may receive a rep-led approach, while another high-potential physician with low field responsiveness may be better suited to coordinated digital engagement. This closes the loop between targeting and engagement measurement. The analytics environment supporting this process also needs to make the results accessible to commercial stakeholders. For organizations modernizing their BI stack, Tableau to Power BI migration can also be part of the broader effort to centralize targeting outputs, monitoring, and commercial reporting. How long does it take to build an HCP targeting model? There is no single timeline that applies to every pharma organization. The scope depends on: Size of the HCP universe Number of data sources Identity resolution requirements Modeling approach Validation requirements CRM or field integration Existing commercial data infrastructure A simple segmentation exercise is very different from a production-ready predictive targeting capability. The project scope should therefore focus on deliverables such as: HCP universe definition Data integration and quality assessment HCP identity resolution Segmentation or predictive model Target scoring Business validation CRM or field integration Performance monitoring The source notes that Perceptive Analytics emphasizes rapid deployment through pre-built life sciences data models, while also noting that the appropriate timeline should be determined after reviewing the client's data environment. How can pharma companies keep an HCP targeting model accurate? Accuracy is an ongoing process, not a one-time modeling exercise. A monitoring framework should track: HCP affiliation changes New prescribing patterns Changes in patient populations Payer access changes Competitive launches Engagement response Model drift Target-list performance Field overrides Business outcomes The model should also have a defined refresh policy. This matters because provider information changes. Physician moves, affiliation changes, and health-system consolidation can create a gap between the current healthcare ecosystem and the information represented in commercial systems. Frequently Asked Questions About HCP Targeting What is HCP targeting in pharma? HCP targeting is the process of identifying and prioritizing healthcare professionals using factors such as prescribing behavior, patient potential, specialty, engagement, payer access, and future commercial opportunity. How do pharma companies build an HCP targeting model? They typically define a commercial objective, establish the HCP universe, integrate relevant commercial data, segment physicians, develop predictive scores where appropriate, validate the results, and connect targets to field or omnichannel engagement. What data is needed for HCP targeting? Common inputs include prescription data, medical claims, HCP master data, patient information, CRM activity, payer information, digital engagement, specialty, affiliations, geography, and competitive data. What is the difference between HCP segmentation and HCP targeting? Segmentation groups HCPs according to shared characteristics. Targeting determines which HCPs or segments should receive commercial investment and how they should be prioritized. Are HCP deciles still useful? Yes. Deciles can provide a useful baseline and can be included within a broader targeting model. They become less sufficient when historical prescription volume is the only measure of HCP potential. How often should HCP target lists be refreshed? The appropriate frequency depends on changes in prescribing behavior, provider data, payer access, and the market. The source cites IQVIA's finding that up to 40% of HCPs can change segments within six months. How does AI improve HCP targeting? AI and machine learning can identify patterns across multiple variables and estimate future prescribing potential, helping commercial teams identify emerging or high-potential HCPs that historical volume alone may overlook. How do you measure HCP targeting effectiveness? Common measures include prescription growth, NRx, TRx, market share, call productivity, engagement response, target-list penetration, and incremental commercial outcomes. Key takeaways An accurate HCP targeting model should do more than rank physicians by historical prescriptions. A practical model should: Start with a clear commercial objective Build a complete and current HCP universe Combine relevant data sources Resolve HCP identities across systems Use segmentation appropriate to the brand and indication Add predictive modeling where it improves the decision Validate results with commercial and field teams Connect targeting with engagement workflows Measure business outcomes rather than model accuracy alone Refresh as physician behavior and market conditions change The central question is not simply which algorithm to use. It is whether the targeting system can identify the HCPs the commercial team should prioritize, explain the reasoning behind that prioritization, and help the team act on the insight. For pharma organizations evaluating HCP targeting as part of a broader commercial analytics strategy, Perceptive Analytics positions HCP targeting alongside prescriber analytics, market access, field performance, and next best action within its life sciences commercial analytics practice.